Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Payables (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Payables for 4 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables rose 2.58% to $1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.1 million, a 2.58% increase, with the full-year FY2024 number at $1.2 million, up 91.63% from a year prior.
  • Payables was $1.1 million for Q3 2025 at bioAffinity Technologies, down from $1.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $1.5 million in Q1 2025 to a low of $146537.0 in Q1 2023.
  • A 4-year average of $753016.5 and a median of $827407.0 in 2023 define the central range for Payables.
  • Peak YoY movement for Payables: soared 388.64% in 2024, then increased 2.58% in 2025.
  • bioAffinity Technologies' Payables stood at $345042.0 in 2022, then skyrocketed by 75.28% to $604789.0 in 2023, then soared by 91.63% to $1.2 million in 2024, then fell by 7.06% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Payables are $1.1 million (Q3 2025), $1.2 million (Q2 2025), and $1.5 million (Q1 2025).